Godavari Biorefineries Limited (GBL) has reported a net loss of Rs 16.02 crore in the quarter ended June 2025, compared to a net loss of Rs 26.11 crore in the same quarter last year. However, sales increased by 2.05% to Rs 533.24 crore. The company’s bio-based chemicals segment recorded a strong 43% year-on-year growth in EBITDA. GBL’s CMD, Samir Somaiya, commented that the quarter was marked by resilience and progress, with improved revenue and EBITDA. The company is focusing on strengthening its bio-based chemicals segment and developing new specialty chemicals. Additionally, GBL has made progress in its drug discovery efforts, with a European patent validated for a novel anti-cancer molecule and a patent granted by the China National Intellectual Property Administration for another anti-cancer molecule. The company is confident of creating sustainable value for stakeholders through its initiatives, including enhancing multi-feedstock ethanol capabilities and investing in research and development. Overall, GBL is poised for long-term growth and innovation in the bio-based chemicals and ethanol segments.
Godavari Biorefineries reports Q1 FY26 revenue of Rs. 534 crore, marking a significant increase in sales.
